News coverage about CymaBay Therapeutics (NASDAQ:CBAY) has trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. CymaBay Therapeutics earned a daily sentiment score of 0.15 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.088092572231 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- CymaBay Therapeutics Inc. (CBAY) Receives New Coverage from Analysts at SunTrust Banks, Inc. (americanbankingnews.com)
- Trading Chatter on CymaBay Therapeutics Inc (CBAY) Shares … – Hayden Business Journal (haydenbusinessjournal.com)
- Finding Support And Resistance On A Chart: Cymabay Therapeutics, Inc. (CBAY), The Walt Disney Company (DIS) – AllStockNews (allstocknews.com)
- Technical Indicators for Cymabay Therapeutics, Inc. (CBAY) in Short Run – StockNewsGazette (stocknewsgazette.com)
- CymaBay Therapeutics (CBAY) Announces the Publication of … – StreetInsider.com (streetinsider.com)
CymaBay Therapeutics (NASDAQ CBAY) traded up 0.32% during midday trading on Friday, hitting $6.26. The stock had a trading volume of 946,917 shares. The stock’s 50-day moving average is $6.62 and its 200-day moving average is $4.51. The company’s market cap is $273.91 million. CymaBay Therapeutics has a one year low of $1.15 and a one year high of $8.29.
CymaBay Therapeutics (NASDAQ:CBAY) last issued its earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.25) by $0.06. Equities analysts predict that CymaBay Therapeutics will post ($0.77) EPS for the current fiscal year.
A number of analysts have recently weighed in on the company. SunTrust Banks, Inc. assumed coverage on CymaBay Therapeutics in a research report on Friday. They set a “buy” rating and a $15.00 price target on the stock. Piper Jaffray Companies reiterated an “overweight” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research report on Tuesday, July 25th. Oppenheimer Holdings, Inc. raised their target price on CymaBay Therapeutics from $8.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, July 20th. Ifs Securities reaffirmed a “strong-buy” rating on shares of CymaBay Therapeutics in a research note on Monday, July 17th. Finally, CIBC reaffirmed an “outperform” rating and set a $15.00 price target (up from $8.00) on shares of CymaBay Therapeutics in a research note on Thursday, July 20th. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $12.32.
WARNING: This piece was first published by BNB Daily and is the property of of BNB Daily. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-cymabay-therapeutics-nasdaqcbay-stock-price-updated.html.
In other news, SVP Charles Mcwherter purchased 5,000 shares of the firm’s stock in a transaction dated Thursday, July 20th. The stock was bought at an average price of $7.43 per share, with a total value of $37,150.00. Following the acquisition, the senior vice president now directly owns 5,100 shares of the company’s stock, valued at $37,893. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sujal Shah bought 10,000 shares of CymaBay Therapeutics stock in a transaction that occurred on Thursday, July 20th. The stock was bought at an average cost of $7.34 per share, with a total value of $73,400.00. Following the completion of the purchase, the insider now owns 75,891 shares in the company, valued at approximately $557,039.94. The disclosure for this purchase can be found here. Insiders have acquired a total of 20,000 shares of company stock valued at $144,750 in the last quarter. Corporate insiders own 15.10% of the company’s stock.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.
Receive News & Ratings for CymaBay Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.